Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma

NCT00521560 is registered in ClinicalTrials.gov with Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH as lead sponsor.

NCT NCT00521560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00521560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma
Lead sponsor
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
August 31, 2012
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd20+ aggressive non-hodgkin's lymphoma, primary non-hodgkin-lymphoma, refractory non-hodgkin-lymphoma